XML 22 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Licensing revenue $ 7,600,000 $ 1,900,000
Operating expenses:    
Cost of revenue 200,000 0
Research and development 15,674,000 9,282,000
General and administrative 11,320,000 9,600,000
In-process research and development impairment charge 5,700,000 0
Total operating expenses 32,894,000 18,882,000
Loss from operations (25,294,000) (16,982,000)
Non-operating income (expense):    
Change in fair value of warrant liability 15,000 (97,000)
Change in fair value of contingent consideration 4,337,000 279,000
Interest income, net 6,000 26,000
Loss before income taxes 4,358,000 208,000
Loss before income taxes (20,936,000) (16,774,000)
Income tax benefit (237,000) (17,000)
Net loss (20,699,000) (16,757,000)
Deemed dividend arising from warrant modifications 0 (78,000)
Net loss attributable to common stockholders, basic (20,699,000) (16,835,000)
Net loss attributable to common stockholders, diluted $ (20,699,000) $ (16,835,000)
Per share information:    
Net loss per common share attributable to common stockholders, basic (in dollars per share) $ (1.34) $ (2.11)
Net loss per common share attributable to common stockholders, diluted (in dollars per share) $ (1.34) $ (2.11)
Weighted-average common shares outstanding, basic (in shares) 15,481,113 7,977,104
Weighted-average common shares outstanding, diluted (in shares) 15,481,113 7,977,104